ADMA Biologics
ADMA
72 hedge funds and large institutions have $165M invested in ADMA Biologics in 2019 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 38 increasing their positions, 10 reducing their positions, and 6 closing their positions.
280% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 10
115% more call options, than puts
Call options by funds: $495K | Put options by funds: $230K
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
22% more capital invested
Capital invested by funds: $136M → $165M (+$29.9M)
7% more funds holding
Funds holding: 67 → 72 (+5)
3.62% more ownership
Funds ownership: 59.06% → 62.69% (+3.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.21M |
| 2 |
Millennium Management
New York
|
+$3.11M |
| 3 |
Barclays
London,
United Kingdom
|
+$1.72M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$1.52M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.49M |
| 2 |
CCM
Consonance Capital Management
New York
|
-$2.47M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$2.27M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$1.13M |
| 5 |
JG
Jefferies Group
New York
|
-$1.11M |
ADMA Hedge Fund Activity: Q3 2019 in Review
72 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q3 2019, worth a combined $165M — up 22% from $136M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ADMA positions and 6 closed out — a net gain of 6 holders — while 38 added to existing stakes and 10 trimmed.
The largest buyer was BlackRock, adding an estimated $5.21M. The largest seller was Schonfeld Strategic Advisors, cutting an estimated $2.49M.
- 72 institutional investors held ADMA Biologics (ADMA) as of Q3 2019, up from 67 in Q2 2019.
- Funds reported $165M of ADMA Biologics stock for Q3 2019, up 22% quarter-over-quarter.
- 12 funds opened new ADMA Biologics positions in Q3 2019 and 6 closed out, a net change of +6 holders.
- The largest ADMA Biologics buyer in Q3 2019 was BlackRock, an estimated $5.21M added.
- The largest ADMA Biologics seller in Q3 2019 was Schonfeld Strategic Advisors, an estimated $2.49M sold.
Based on aggregated 13F filings for Q3 2019.